|
 |
Fluocinolone AcetonideThis page contains recent news articles, when available, and an overview of Fluocinolone Acetonide but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.We have one product candidate in Phase III clinical trials: Medidur with fluocinolone acetonide ("FA") for the treatment of diabetic macular edema ("DME") Sydney Morning Herald, Alimera Files IPO as Experts Predict Capital Markets Crisis - 03 Jul 2008 For the treatment of DME, Iluvien delivers the nonproprietary corticosteroid fluocinolone acetonide. The approach also may be applicable in treating TMCnet Alimera Reports Results From the Three-Month Interim Readout of ... - Jun 26, 2008 This 36-month, open-label Phase 2 study, running concurrently with the pivotal Phase 3 FAME(TM) Study (Fluocinolone Acetonide in Diabetic Macular Edema), FOXBusiness Alimera Sciences reports 3-month results for Medidur FA implant study - Jun 26, 2008 The 36-month, open-label phase 2 study — which coincides with the pivotal phase 3 FAME (Fluocinolone acetonide in diabetic macular edema) study — is OSN SuperSite (subscription), pSivida to begin clinical trial - May 8, 2008 ...of the Medidur product, which is a small injectable intravitreal device, designed to release fluocinolone acetonide to the retina for up to three years. WA Business News (subscription), Pilot Study to Assess Safety and Efficacy of Medidur(TM) FA in AMD ... - May 8, 2008 Medidur FA, a tiny, injectable intravitreal insert, is currently being studied as a way to deliver a very low dose of fluocinolone acetonide, Earthtimes (press release), pSivida Announces Start Of Clinical Trial To Assess Safety And - May 12, 2008 Medidur FA is a tiny injectable intravitreal device designed to release fluocinolone acetonide to the retina for up to three years. Medical Design Online, pSivida Announces Start of Clinical Trial to Assess Safety and ... - May 8, 2008 Medidur FA is a tiny injectable intravitreal device designed to release fluocinolone acetonide to the retina for up to three years. Business Wire (press release), Information Memorandum - US Reincorporation - May 5, 2008 ...the first human pharmacokinetic (PK) study of fluocinolone acetonide (FA) in the companies' Medidur FA for DME product candidate; 7 On 27 August 2007, Sydney Morning Herald, Getting Past the Pain of Common Cosmetic Procedures - Mar 26, 2008 Clobex® shampoo, lotion and spray (clobetasol propionate 0.05%) and Tri-Luma® Cream (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%). Market Wire (press release) DSMB gives backing to Medidur - Mar 26, 2008 The Medidur technology is a tiny injectable device 3mm long and 0.37mm in diameter which delivers 0.2 or 0.5 micrograms of drug (fluocinolone acetonide, In-PharmaTechnologist.com, DSMB Again Supports Continuation Of The Phase III Clinical Trial ... - Mar 25, 2008 Medidur, a tiny, injectable insert, is being studied as a way to deliver fluocinolone acetonide, a corticosteroid, to the retina for up to three years as a Medical News Today (press release), Alimera Sciences Signs Second Agreement With Emory University for ... - Feb 26, 2008 Alimera has recently completed enrollment of its 956-patient phase III clinical trial of fluocinolone acetonide in the Medidur(TM) drug delivery system for Earthtimes, Medicis to Present At Merrill Lynch Conference - Feb 5, 2008 0.05%, VANOS(R) (fluocinonide) Cream, 0.1%, SYNALAR(R) (fluocinolone acetonide), and ZIANA(R) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, FOXBusiness Medicis to Present At 2007 Credit Suisse Annual Healthcare Conference - Nov 12, 2007 0.05%, VANOS(R) (fluocinonide) Cream, 0.1%, SYNALAR(R) (fluocinolone acetonide), and ZIANA(R) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, CNNMoney.com Fluocinolone acetonide implant causes significant but manageable ... - Oct 10, 2007 Treating patients who have uveitis with an intravitreal implant that delivers fluocinolone acetonide can cause significant elevations in IOP, a study found. OSN SuperSite (subscription), Enrollment Complete in Pivotal Phase 3 Trial of Medidur(TM) FA for ... - Oct 8, 2007 Medidur, a tiny, injectable insert, is being studied as a way to deliver fluocinolone acetonide, a corticosteroid, to the retina for up to three years as a CNNMoney.com Enrollment complete for phase 3 trial of drug delivery insert for ... - Oct 9, 2007 ATLANTA — Enrollment in the phase 3 Fluocinolone Acetonide in Diabetic Macular Edema clinical trial evaluating the Medidur FA drug delivery implant has been OSN SuperSite (subscription), Enrollment Complete in Medidur FA Trial - Oct 8, 2007 Alimera Sciences and pSivida have completed enrollment in a Phase III trial, the Fluocinolone Acetonide in Diabetic Macular Edema (FAME) study of Medidur FA FDA news (subscription), Medicis to Present At Leerink Swann Aesthetics Roundtable Conference - Oct 1, 2007 0.05%, VANOS(R) (fluocinonide) Cream, 0.1%, SYNALAR(R) (fluocinolone acetonide), and ZIANA(TM) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, CNNMoney.com New approaches to the treatment of melasma aim at improving ... - Oct 4, 2007 Pearl Grimes was Tri-Luma® Cream,* *(TC)* *combining hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01% (a low-potency corticosteroid). PharmaLive.com (press release), Enrollment begins for pharmacokinetic study of Medidur ... - Aug 22, 2007 ATLANTA — Alimera Sciences and pSivida Limited have begun enrolling patients in the first human pharmacokinetic study of the Medidur fluocinolone acetonide OSN SuperSite (subscription), Enrollment Begins on Human PK Study for Medidur(TM) FA - Aug 22, 2007 Medidur FA is currently in a Phase III global clinical trial, the FAME(TM) (Fluocinolone Acetonide in Diabetic Macular Edema) Study that will follow CNNMoney.com PSivida, partner prepare new study for Medidur - Aug 22, 2007 Medidur is a tiny insert, injected during an in-office procedure, which is being studied as a way to deliver a very low dose of fluocinolone acetonide, Bizjournals.com, WINS: contracts, partnerships, clinical trials, wireless buildouts - Aug 22, 2007 ...pharmacokinetic study of fluocinolone acetonide in Medidur, the companies’ investigational product for the treatment of diabetic macular edema (DME). TechJournal South, Medicis to Present At Thomas Weisel Partners Healthcare Conference - Sep 4, 2007 0.05%, VANOS(R) (fluocinonide) Cream, 0.1%, SYNALAR(R) (fluocinolone acetonide), and ZIANA(TM) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, CNNMoney.com Galderma Laboratories Names Brand Pharm Agency of Record for ... - Sep 4, 2007 The third product - TRI-LUMA® (fluocinolone acetonide 0.01 percent, hydroquinone 4 percent, tretinoin 0.05 percent), a treatment for melasma, PharmaLive.com (press release), Medicis and Hyperion Therapeutics Announce Strategic Collaboration - Aug 28, 2007 SYNALAR(R) (fluocinolone acetonide), and ZIANA(TM) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, and the over-the-counter brand ESOTERICA(R). CNNMoney.com Market Report -- In Play (WIRES) - Aug 22, 2007 Alimera Sciences and pSivida (PSDV) announce that enrollment has begun for the first human pharmacokinetic study of fluocinolone acetonide in Medidur, MSN Money B&L board to decide on merger proposals - Jul 23, 2007 Rochester Democrat and Chronicle,Retisert is used to administer an anti-inflammatory agent, fluocinolone acetonide, to the back of the eye. The implant holds roughly a 30-month supply. Medicis Announces Second Quarter 2007 Conference Call and Webcast - Aug 2, 2007 CNNMoney.com0.05%, VANOS(TM) (fluocinonide) Cream, 0.1%, SYNALAR(R) (fluocinolone acetonide), and ZIANA(TM) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, Bausch & Lomb Acquires Soothe(R) Emollient (Lubricant) Eye Drops ... - Aug 1, 2007 Genetic Engineering News (press release),...fluocinolone acetonide (FA) in the Medidur(TM) delivery technology, an investigational product for the treatment of diabetic macular edema (DME). pSivida Strengthens its Position in Drug Delivery Sector - Jul 18, 2007 Business Wire (press release),...failure of Medidur™ to release fluocinolone acetonide at the same rate as Retisert™; our inability to recruit patients for the phase III Medidur™ for Medicis Provides Notice to All Holders of Convertible Notes Due ... - Jun 12, 2007 CNNMoney.com0.05%, VANOS(TM) (fluocinonide) Cream, 0.1%, SYNALAR(R) (fluocinolone acetonide), and ZIANA(TM) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, Medicis Begins Shipping PERLANE to Physicians - May 21, 2007 Primenewswire (press release),0.05%, VANOS(TM) (fluocinonide) Cream, 0.1%, SYNALAR(R) (fluocinolone acetonide), and ZIANA(TM) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, Medidur Trial Exceeds 500 Patient Mark In Phase 3 Trial Enrollment - Apr 24, 2007 eMaxHealth.com,Medidur, a tiny, injectable intravitreal insert, is being studied as a way to deliver a very low dose of fluocinolone acetonide, a corticosteroid,to the Alimera Sciences' Medidur Trial Exceeds 500 Patient Mark in Phase ... - Apr 23, 2007 PharmaLive.com (press release),Medidur, a tiny, injectable intravitreal insert, is being studied as a way to deliver a very low dose of fluocinolone acetonide, a corticosteroid, pSivida Signs $165 Million(US) Collaborative Research and ... - Apr 5, 2007 Nanotechwire.com,Medidur in combination with Fluocinolone Acetonide is in Phase III clinical trials in DME in collaboration with Alimera Sciences Inc., Pfizer spies pSivida's injectable eye treatment - Apr 4, 2007 DrugResearcher.com,The insert is being studied as a way of delivering fluocinolone acetonide (a corticosteroid) to treat diabetic macular edema (DME), and has been designed to pSivida Completes US$2.9m Placement - Dec 20, 2006 Genetic Engineering News (press release),Medidur(TM) for the delivery of a steroid (fluocinolone acetonide) for the treatment of the chronic eye disease diabetic macular edema (DME). Medicis to Present At JPMorgan 25th Annual Healthcare Conference - Jan 4, 2007 PharmaLive.com (press release),0.05%, VANOS(TM) (fluocinonide) Cream, 0.1%, SYNALAR(R) (fluocinolone acetonide), ZIANA(TM) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, pSivida Enters Licensing Negotiations with Major Global Pharma for ... - Dec 27, 2006 dBusinessNews Boston (press release),...failure of Medidur™ to release fluocinolone acetonide at the same rate as Retisert™; our inability to recruit patients for the Phase III Medidur™ for pSivida Enters Licensing Negotiations with Major Global Pharma for ... - Dec 26, 2006 PharmaLive.com (press release),...diabetic retinopathy severity score as Retisert(TM) for DME; failure of Medidur(TM) to release fluocinolone acetonide at the same rate as Retisert(TM); Alimera Sciences and Bausch & Lomb Announce Transaction for Alaway ... - Dec 20, 2006 dBusinessNews Atlanta (press release),2005 to study diabetic macular edema (DME) patients treated using Medidur™ with fluocinolone acetonide, the company’s pharmacologic treatment for DME. pSivida Enters Licensing Negotiations with Major Global Pharma for ... - 26 Dec 2006 Business Wire (press release),...improvement in visual acuity and diabetic retinopathy severity score as Retisert™ for DME; failure of Medidur™ to release fluocinolone acetonide at the ... pSivida raises $3.7m, re-appoints Aston to board - Dec 19, 2006 WA Business News,...fund pSivida's portion of costs to develop its lead ophthalmic development product, MedidurTM for the delivery of a steroid (fluocinolone acetonide) for the ... Alimera Sciences and Bausch & Lomb Announce Transaction for Alaway ... - Dec 20, 2006 dBusinessNews Atlanta (press release),...a Phase III clinical trial in October 2005 to study diabetic macular edema (DME) patients treated using Medidur™ with fluocinolone acetonide, the company’s ... Medicis Declares Cash Dividend - Dec 14, 2006 Primenewswire (press release),Tablets, TRIAZ(R) (benzoyl peroxide), LIDEX(R) (fluocinonide) Cream, 0.05%, VANOS(TM) (fluocinonide) Cream, 0.1%, SYNALAR(R) (fluocinolone acetonide), ZIANA(TM ... Alimera Sciences Completes Second Tranche of Series B Financing ... - Nov 27, 2006 Yahoo! News (press release)2005 initiated a Phase III clinical trial to study diabetic macular edema (DME) patients treated using Medidur(TM) with fluocinolone acetonide, the company's ... Medicis and Dow Pharmaceutical Sciences Announce FDA Approval of ... Nov 7, 2006 Tablets, TRIAZ(R) (benzoyl peroxide), LIDEX(R) (fluocinonide) Cream, 0.05%, VANOS(TM) (fluocinonide) Cream, 0.1%, SYNALAR(R) (fluocinolone acetonide), and ZIANA ... -PrimeZone (press release), Medicis Announces Third Quarter 2006 Conference Call and Webcast Nov 6, 2006 TRIAZ(R) (benzoyl peroxide), LIDEX(R) (fluocinonide) Cream, 0.05%, VANOS(TM) (fluocinonide) Cream, 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R ... -PrimeZone (press release), First Patient Implanted in pSivida European Pancreatic Cancer ... Oct 9, 2006 ...improvement in visual acuity and diabetic retinopathy severity score as Retisert™ for DME; failure of Medidur™ to release fluocinolone acetonide at the ... -Business Wire (press release), Misunderstood and Often Untreated: Melasma, or ‘Pano,’ Affects ... Oct 17, 2006 ...prompt discontinuation of therapy. Tri-Luma(R) Cream contains the corticosteroid fluocinolone acetonide. Systematic absorption of ... -Hispanic PR Wire (press release), First Patient Implanted in pSivida European Pancreatic Cancer ... Oct 9, 2006 ...improvement in visual acuity and diabetic retinopathy severity score as Retisert(TM) for DME; failure of Medidur(TM) to release fluocinolone acetonide at the ... -Genetic Engineering News (press release), Medicis to Present at UBS Global Life Sciences Conference Sep 22, 2006 TRIAZ(R) (benzoyl peroxide), LIDEX(R) (fluocinonide) Cream, 0.05%, VANOS(TM) (fluocinonide) Cream, 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R ... -PrimeZone pSivida: Retisert(TM) Wins International Award Sep 13, 2006 ...'Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis' published in Ophthalmology 2005 and co-authored ... -Business Wire Initiation of Phase II Clinical Study of Novel Ophthalmic Product Sep 19, 2006 ...improvement in visual acuity and diabetic retinopathy severity score as Retisert(TM) for DME; failure of Medidur(TM) to release fluocinolone acetonide at the ... -PharmaLive.com Non-Exec Director Resigns from pSivida Board Aug 28, 2006 ...improvement in visual acuity and diabetic retinopathy severity score as Retisert(TM) for DME; failure of Medidur(TM) to release fluocinolone acetonide at the ... -Genetic Engineering News Medicis Announces Second Quarter 2006 Conference Call and Webcast Jul 31, 2006 TRIAZ(R) (benzoyl peroxide), LIDEX(R) (fluocinonide) Cream, 0.05%, VANOS(TM) (fluocinonide) Cream, 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R ... -PrimeZone : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |